Prognostic impact of postoperative systemic inflammatory response in patients with stage II/III gastric cancer

Kenji Kuroda, Takahiro Toyokawa*, Yuichiro Miki, Mami Yoshii, Tatsuro Tamura, Hiroaki Tanaka, Shigeru Lee, Kazuya Muguruma, Masakazu Yashiro & Masaichi Ohira

This study examined whether the systemic inflammatory response present in the early phase of the postoperative state correlates with long-term outcomes and to identify markers in patients with stage II/III gastric cancer. 444 consecutive patients who underwent radical gastrectomy for stage II/III gastric cancer were retrospectively reviewed. We evaluated maximum serum C-reactive protein (CRPmax) and white blood cell count (WBCmax), defined as the maximum serum CRP level and maximum WBC count during the interval from surgery until discharge, as systemic inflammation markers. In univariate analyses, CRPmax, WBCmax and infectious complications were significantly associated with both overall survival (OS) ($p < 0.001$, $p < 0.001$ and $p = 0.011$, respectively) and relapse-free survival (RFS) ($p < 0.001$, $p = 0.001$ and $p < 0.001$, respectively). Multivariate analysis revealed that high-CRPmax (> 9.2 mg/dL) was an independent prognostic factor for OS (hazard ratio (HR) 1.68, 95% confidence interval (CI) 1.19–2.36, $p = 0.003$) and RFS (HR 1.56, 95% CI 1.12–2.18, $p = 0.009$), while WBCmax and infectious complications were not. CRPmax, which reflects the magnitude of systemic inflammation induced by surgical stress and postoperative complications in the early phase after surgery, may be a promising prognostic indicator in patients with stage II/III gastric cancer who undergo curative resection.

Abbreviations
CRP C-reactive protein
WBC White blood cell
BMI Body mass index
PS Performance status
DG Distal gastrectomy
PG Proximal gastrectomy
TG Total gastrectomy
U Upper
M Middle
L Lower
OS Overall survival
RFS Relapse-free survival

Gastric cancer is the fifth most common fatality-causing and the third leading morbidity-causing carcinoma in the world1. Evolutions in diagnosis and multimodal therapy have improved treatment outcomes. However, the prognosis of gastric cancer patients with stage II or III disease remains insufficient. According to a retrospective analysis of nationwide data from the Japanese Gastric Cancer Association, 5-year overall survival rates for gastric cancer patients were 70.6% in stage II, 53.6% in stage IIIA and 34.8% in stage IIIB2. The ACTS-GC trial showed that 5-year overall survival rates of patients who underwent radical gastrectomy with D2 lymph node dissection followed by adjuvant chemotherapy were 84.2% in stage II, 67.1% in stage IIIA and 50.2% in stage IIIB. To further improve the prognosis of patients treated with standard treatment, identifying prognostic factors is important.

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. *email: t-toyokawa@med.osaka-cu.ac.jp
Inflammation has been revealed to be closely related to the progression and metastasis of cancer cells. Several studies have shown that postoperative infectious complications correlate with postoperative recurrence and poor prognosis in various malignancies, including gastric cancer. Systemic inflammatory responses caused by infectious complications could induce not only the proliferation of residual cancer cells, but also declines in host immunity, which may lead to worsened prognosis. On the other hand, in the postoperative early phase, surgical stress also induces systemic inflammatory responses. Several recent studies have focused on the association between long-term outcome and postoperative systemic inflammatory response caused by surgical stress and complications in gastroenterological cancer. However, the significance of postoperative inflammatory response in the early phase after surgery and its markers in patients with gastric cancer remain uncertain. The aim of this study was to examine whether the systemic inflammatory response caused in the early phase of the postoperative state correlates with prognosis in advanced gastric cancer patients who undergo curative resection. We evaluated C-reactive protein (CRP) and white blood cell (WBC) count as simple and versatile markers of postoperative systemic inflammation in clinical practice that may be suitable for detecting the magnitude of inflammatory reaction.

Results
Predictive ability and cut-off values for CRP max and WBC max.
Median CRP max and WBC max were 10.4 mg/dL (interquartile range [IQR], 7.3–14.9 mg/dL) and 11,000/mm³ (IQR, 9,200–13,900/mm³), respectively. Areas under the curve predicting 5-year OS were 0.615 for CRP max and 0.573 for WBC max, respectively. Values of 9.2 mg/dL for CRP max and 15,100/mm³ for WBC max provided maximal Youden indices, and were thus set as the cut-off values. We classified 258 patients (58.1%) and 186 patients (41.9%) as having high-CRP max and low-CRP max, respectively, and 83 patients (18.7%) and 361 patients (81.3%) as having high-WBC max and low-WBC max, respectively.

Correlations between CRP max, WBC max, age, BMI, and PS. Table 1 shows the associations between CRP max, WBC max, and clinicopathological variables. CRP max was significantly associated with operative procedure, operation time, blood loss, tumor size, tumor location, and postoperative infectious complications (p < 0.001 each). WBC max was significantly associated with operative procedure, operation time, blood loss, tumor size, tumor location, and postoperative infectious complications (p < 0.001 each).

Survival and prognostic factors.
Median follow-up for survivors was 88 months (IQR, 73–122 months). Thirteen patients were lost to follow-up within 5 years, with 16 months as the shortest follow-up period for survivors. Recurrence was observed in 162 cases, and median duration to recurrence was 15 months (IQR, 8–29 months). A total of 200 deaths were observed.

Five-year OS and RFS rates for the entire study population were 59.0% and 55.2%, respectively. OS and RFS rates in patients with high-CRP max were significantly poorer than those of patients with low-CRP max (p < 0.001 each) (Fig. 1). OS and RFS rates in patients with high-WBC max were also significantly poorer than those of patients with low-WBC max (p < 0.001 and p = 0.001, respectively) (Fig. 2).

Results of uni- and multivariate analyses for OS and RFS are summarized in Tables 2 and 3, respectively. Univariate analyses for OS revealed significant correlations with CRP max, WBC max, age, BMI, PS, operative procedure, operative approach, operation time, blood loss, lymph node status, pathological stage, postoperative infectious complications, and adjuvant chemotherapy. Multivariate analysis for OS indicated that CRP max (HR 1.68, 95%CI 1.19–2.36, p = 0.003), BMI (HR 0.59, 95%CI 0.40–0.86, p = 0.007), PS (HR 1.43, 95%CI 1.01–2.04, p = 0.047), pathological stage (HR 2.41, 95%CI 1.78–3.26, p < 0.001) and adjuvant chemotherapy (HR 0.68, 95%CI 0.48–0.95, p = 0.007) were independent prognostic factors. Univariate analyses for RFS revealed significant correlations with CRP max, WBC max, age, BMI, PS, operative procedure, operative approach, blood loss, pathological stage, and postoperative infectious complications. Multivariate analysis for RFS indicated CRP max (HR 1.56, 95%CI 1.12–2.18, p = 0.009), age (HR 1.42, 95%CI 1.01–1.98, p = 0.042), BMI (HR 0.66, 95%CI 0.45–0.96, p = 0.032), PS (HR 1.30, 95%CI 1.04–1.61, p = 0.020) and pathological stage (HR 2.23, 95%CI 1.67–2.98, p < 0.001) as independent prognostic factors.

Subgroup analysis for OS according to adjuvant chemotherapy and postoperative infectious complications.
Figure 3A and B show the Kaplan–Meier survival curves comparing OS for CRP max according to adjuvant chemotherapy. In patients with and without adjuvant chemotherapy, OS rates were significantly lower in the high-CRP max group than in the low-CRP max group (p = 0.002 and p < 0.001, respectively). Figure 3C and D show the Kaplan–Meier survival curves comparing OS for CRP max according to postoperative infectious complications. In patients without postoperative infectious complications, OS rates were significantly lower in the high-CRP max group than in the low-CRP max group (p < 0.001), whereas in the presence of postoperative infectious complications, no significant difference was observed between groups (p = 0.444); this was attributed to the fact that only 3 patients were included in the low-CRP max group. Therefore, we used another cut-off value of 26.2 mg/dL for patients with postoperative infectious complications, determined based on the same method used for the entire cohort. In patients with postoperative infectious complications, OS rates were significantly lower in this new high-CRP max (> 26.2 mg/dL) group than in the new low-CRP max (≤ 26.2 mg/dL) group (p = 0.015) (Fig. 4).

We classified patients according to CRP max and postoperative infectious complication status into three groups as follows: Group 1, high-CRP max with postoperative infectious complications; Group 2, either high-CRP max or the presence of postoperative infectious complications; and Group 3, low-CRP max without postoperative infectious complications.
Table 1. Patient characteristics. Values in parentheses are percentages unless indicated otherwise; values are all median (i.q.r.) BMI body mass index, PS performance status, DG distal gastrectomy, PG proximal gastrectomy, TG total gastrectomy, U upper, M middle, L lower. *According to the 7th edition of the International Union Against Cancer. †Intra-abdominal abscess, anastomotic leakage, pancreatic fistula, pneumonia, surgical site infection, acute cholecystitis, and enteritis Grade ≥ 2 based on the Clavien-Dindo classification.

| Characteristics                      | High-CRP<sub>max</sub> (n = 258) | Low-CRP<sub>max</sub> (n = 186) | p value | High-WBC<sub>max</sub> (n = 83) | Low-WBC<sub>max</sub> (n = 361) | p value |
|--------------------------------------|----------------------------------|----------------------------------|---------|------------------------------|------------------------------|---------|
| Age (years)                          |                                  |                                  | 0.909   |                              |                              | 0.775   |
| <75                                  | 199 (77.1%)                      | 142 (76.3%)                      |         | 65 (78.3%)                   | 276 (76.5%)                   |         |
| ≥75                                  | 59 (22.9%)                       | 44 (23.7%)                       | 18 (21.7%) | 85 (23.5%)                   |         |         |
| Sex                                  |                                  |                                  | 0.136   |                              |                              | 0.336   |
| Male                                 | 195 (75.6%)                      | 109 (58.6%)                      | 61 (67.3%) | 243 (73.5%)                   |         |         |
| Female                               | 63 (24.4%)                       | 77 (41.4%)                       | 22 (32.7%) | 118 (26.5%)                   |         |         |
| BMI (kg/m<sup>2</sup>)              |                                  |                                  | 0.141   |                              |                              | 0.852   |
| <18.5                                | 26 (10.1%)                       | 28 (15.1%)                       | 9 (10.8%) | 45 (12.5%)                   |         |         |
| ≥18.5                                | 232 (89.9%)                      | 158 (84.9%)                      | 74 (89.2%) | 316 (87.5%)                   |         |         |
| PS                                   |                                  |                                  | 0.658   |                              |                              | 0.566   |
| 0                                    | 201 (77.9%)                      | 149 (80.1%)                      | 63 (75.9%) | 287 (79.5%)                   |         |         |
| 1–2                                  | 57 (22.1%)                       | 37 (19.9%)                       | 20 (24.1%) | 74 (20.5%)                   |         |         |
| Operative approach                   |                                  |                                  | 0.113   |                              |                              | 0.326   |
| Open                                 | 246 (95.3%)                      | 170 (91.4%)                      | 80 (96.4%) | 236 (93.1%)                   |         |         |
| Laparoscopic                         | 12 (4.7%)                        | 16 (8.6%)                        | 3 (3.6%) | 25 (6.9%)                     |         |         |
| Operative procedure                  | <0.001                           |                                  | <0.001  |                              |                              |         |
| DG, PG                               | 122 (46.9%)                      | 140 (75.3%)                      | 24 (28.9%) | 238 (65.7%)                   |         |         |
| TG                                   | 136 (52.7%)                      | 46 (24.7%)                       | 59 (71.1%) | 123 (34.1%)                   |         |         |
| Operation time (min)                 | 230 [199–282]                    | 194 [171–233]                    | <0.001  | 250 [204–293]                 | 210 [180–248]                 | <0.001  |
| Blood loss (ml)                      | 448 [290–660]                    | 253 [150–394]                    | <0.001  | 530 [310–778]                 | 330 [190–500]                 | <0.001  |
| Tumor size (mm)                      | 55 [15–200]                      | 45 [10–130]                      | <0.001  | 64 [15–90]                    | 50 [10–200]                    | <0.001  |
| Depth of invasion                    | 0.221                            | 0.248                            |         |                              |                              |         |
| T1–2                                 | 45 (17.4%)                       | 42 (22.6%)                       | 12 (14.5%) | 75 (20.8%)                   |         |         |
| T3–4                                 | 213 (82.6%)                      | 144 (77.4%)                      | 71 (85.5%) | 286 (79.2%)                   |         |         |
| Lymph node metastasis               | 0.285                            |                                  | 0.89     |                              |                              |         |
| N0                                   | 66 (25.6%)                       | 57 (30.6%)                       | 24 (28.9%) | 99 (27.4%)                   |         |         |
| N1–3                                 | 192 (74.4%)                      | 129 (69.4%)                      | 59 (71.1%) | 262 (72.6%)                   |         |         |
| pStage†                              | 0.106                            |                                  | 0.229    |                              |                              |         |
| II                                   | 123 (47.7%)                      | 104 (55.9%)                      | 37 (44.6%) | 190 (52.6%)                   |         |         |
| III                                  | 135 (52.3%)                      | 82 (44.1%)                       | 46 (55.4%) | 171 (47.4%)                   |         |         |
| Tumor location                       | <0.001                           |                                  | <0.001   |                              |                              |         |
| U                                     | 98 (38.0%)                       | 31 (16.7%)                       | 38 (45.8%) | 91 (25.2%)                   |         |         |
| M                                     | 68 (26.4%)                       | 80 (43.0%)                       | 20 (24.1%) | 128 (35.5%)                   |         |         |
| L                                     | 79 (30.6%)                       | 71 (38.2%)                       | 17 (20.5%) | 133 (36.8%)                   |         |         |
| UML                                   | 13 (5.0%)                        | 4 (2.2%)                         | 8 (9.6%) | 9 (2.5%)                      |         |         |
| Histology                             | 0.408                            |                                  | 0.135    |                              |                              |         |
| Differentiated                       | 121 (46.9%)                      | 79 (42.5%)                       | 44 (53.0%) | 156 (43.2%)                   |         |         |
| Undifferentiated                     | 117 (53.1%)                      | 107 (58.5%)                      | 39 (47.0%) | 205 (56.8%)                   |         |         |
| Postoperative infectious complica- tion* | <0.001                         |                                  | <0.001   |                              |                              |         |
| Absent                               | 190 (73.6%)                      | 183 (98.4%)                      | 45 (54.2%) | 328 (90.9%)                   |         |         |
| Present                              | 68 (26.4%)                       | 3 (1.6%)                         | 38 (45.8%) | 33 (9.1%)                     |         |         |
| Adjuvant chemotherapy                | 0.526                            |                                  | 0.804    |                              |                              |         |
| Absent                               | 60 (23.3%)                       | 49 (26.3%)                       | 19 (22.9%) | 90 (26.3%)                   |         |         |
| Present                              | 188 (76.7%)                      | 137 (73.7%)                      | 64 (77.1%) | 271 (73.7%)                   |         |         |

Table 1. Patient characteristics. Values in parentheses are percentages unless indicated otherwise; values are all median (i.q.r.) BMI body mass index, PS performance status, DG distal gastrectomy, PG proximal gastrectomy, TG total gastrectomy, U upper, M middle, L lower. *According to the 7th edition of the International Union Against Cancer. †Intra-abdominal abscess, anastomotic leakage, pancreatic fistula, pneumonia, surgical site infection, acute cholecystitis, and enteritis Grade ≥ 2 based on the Clavien-Dindo classification.

As shown in Fig. 5, this classification allowed clear separation of survival curves. The five-year OS rates in Groups 1, 2 and 3 were 73.5%, 56.5% and 43.1%, respectively (Group 1 vs Group 2: p < 0.001, Group 1 vs Group 3: p < 0.001, Group 2 vs Group 3: p = 0.051).
Figure 1. Kaplan–Meier survival curves of overall survival (OS) and relapse-free survival (RFS) according to CRP$_{\text{max}}$ in patients with stage II/III gastric cancer. (A) The five-year OS rates are 66.1% in the low-CRP$_{\text{max}}$ group and 45.6% in the high-CRP$_{\text{max}}$ group ($p < 0.001$). (B) The five-year RFS rates are 63.5% in the low-CRP$_{\text{max}}$ group and 44.4% in the high-CRP$_{\text{max}}$ group ($p < 0.001$).

Figure 2. Kaplan–Meier survival curves of overall survival (OS) and relapse-free survival (RFS) according to WBC$_{\text{max}}$ in patients with stage II/III gastric cancer. (A) The five-year OS rates were 58.1% in the low-WBC$_{\text{max}}$ group and 37.4% in the high-WBC$_{\text{max}}$ group ($p < 0.001$). (B) The five-year RFS rate were 56.1% in the low-WBC$_{\text{max}}$ group and 36.1% in the high-WBC$_{\text{max}}$ group ($p = 0.001$).

Table 2. Univariate and multivariate analysis for overall survival.

| Variable                                | Univariate analysis | Multivariate analysis |
|-----------------------------------------|---------------------|-----------------------|
|                                        | Hazard ratio (95% CI) | $p$ value | Hazard ratio (95% CI) | $p$ value |
| CRP$_{\text{max}}$ > 9.2 mg/dL          | 1.93 (1.43–2.61)    | < 0.001              | 1.68 (1.19–2.36)    | 0.003     |
| WBC$_{\text{max}}$ > 15,100 /μL         | 1.72 (1.25–2.37)    | < 0.001              | 0.99 (0.68–1.44)    | 0.972     |
| Age ≥ 75 years                          | 1.86 (1.37–2.52)    | 0.002                | 1.37 (0.95–1.97)    | 0.093     |
| Female (vs. Male)                       | 0.91 (0.67–1.23)    | 0.519                |                      |           |
| BMI ≥ 18.5 kg/m$^2$                     | 0.64 (0.44–0.93)    | 0.021                | 0.59 (0.40–0.86)    | 0.007     |
| PS > 0                                  | 1.81 (1.33–2.47)    | < 0.001              | 1.43 (1.01–2.04)    | 0.047     |
| Operation time                          | 1.002 (1.001–1.004) | < 0.001              | 1.001 (0.99–1.003)  | 0.487     |
| Blood loss                              | 1.001 (1.000–1.001) | 0.011                | 1.000 (0.99–1.000)  | 0.898     |
| Operative procedure: TG                 | 1.88 (1.43–2.46)    | < 0.001              | 1.33 (0.96–1.85)    | 0.086     |
| Operative approach: laparoscopy         | 0.45 (0.21–0.96)    | 0.039                | 0.62 (0.28–1.38)    | 0.241     |
| Histology: undifferentiated             | 1.20 (0.90–1.59)    | 0.207                |                      |           |
| Stage III (vs. II)                      | 2.50 (1.87–3.35)    | < 0.001              | 2.41 (1.78–3.26)    | < 0.001   |
| Postoperative infectious complication    | 1.64 (1.12–2.41)    | 0.011                | 1.18 (0.80–1.73)    | 0.410     |
| Adjuvant chemotherapy                   | 0.71 (0.52–0.97)    | 0.029                | 0.68 (0.48–0.95)    | 0.007     |
Correlation between postoperative inflammatory response and site of recurrence. Sites of first recurrence according to CRPmax and WBCmax are shown in Table 4. The proportion of patients with hematogenous recurrence was significantly higher in the high-CRPmax group (16.3%) and the high-WBCmax group (20.5%) than in the low-CRPmax group (3.8%, \( p < 0.001 \)) and the low-WBCmax group (8.9%), respectively. Whereas no significant difference was evident between CRPmax and peritoneal recurrence, lymph node recurrence, and local recurrence, and the same applied to WBCmax.
Figure 4. Kaplan–Meier survival curves of overall survival (OS) according to CRP$_{\text{max}}$ in patients with postoperative infectious complications ($p = 0.015$).

Figure 5. Kaplan–Meier survival curves of overall survival (OS) according to CRP$_{\text{max}}$ and postoperative infectious complication status (Group 1, high-CRP$_{\text{max}}$ with postoperative infectious complications; Group 2, either high-CRP$_{\text{max}}$ or the presence of postoperative infectious complications; Group 3, low-CRP$_{\text{max}}$ without postoperative infectious complications). The five-year OS rates in Groups 1, 2 and 3 were 73.5%, 56.5% and 43.1%, respectively (Group 1 vs Group 2: $p < 0.001$, Group 1 vs Group 3: $p < 0.001$, Group 2 vs Group 3: $p = 0.051$).

Table 4. Recurrence patterns.
Discussion
The present study investigated correlations between postoperative systemic inflammatory response and prognosis in advanced gastric cancer patients who underwent curative resection, using the maximum postoperative CRP level and WBC count during hospitalization after gastrectomy as markers of systemic inflammation. We found that CRPmax with a cut-off of 9.2 mg/dL was an independent prognostic factor, but WBCmax was not. Further, CRPmax affected OS and RFS independent of postoperative infectious complications. These results suggest that systemic inflammatory response as represented by CRPmax in the early phase after surgery induced by surgical stress and complications is associated with recurrence and survival in patients with stage II/III gastric cancer.

This study revealed CRPmax as an independent prognostic indicator for OS and RFS in patients with stage II/III gastric cancer who underwent curative resection. Consistent with our results, previous studies have demonstrated that postoperative systemic inflammatory response correlated with recurrence and poor prognosis in gastrointestinal cancers including gastric cancer, esophageal cancer, and colorectal cancer. However, the optimal marker remains uncertain. Because the magnitude of surgical stress and postoperative complications can differ markedly among cancers, optimal markers and the respective cut-off values should be determined for each cancer. Okumura et al. revealed postoperative prolonged hyperthermia, defined as a maximum body temperature > 38 °C for ≥ 4 days, as an independent prognostic factor for OS and RFS in patients with stage II/III gastric cancer. Whether postoperative prolonged hyperthermia affected survival independent of the occurrence of postoperative infectious complications was unclear because postoperative complications were strongly associated with prolonged hyperthermia in that study. We evaluated WBCmax and CRPmax as markers that are not only commonly used to estimate the magnitude of inflammation in postoperative management, but also simple and readily available in daily clinical practice. Consequently, we found that CRPmax was an independent prognostic factor for OS and RFS, but WBCmax was not. Similarly, Saito et al. demonstrated that postoperative CRPmax (≥ 12 mg/dL) was an independent prognostic factor for RFS in advanced gastric cancer, although postoperative WBCmax was not. Further, this finding was validated in their subsequent large-scale multicenter study. Postoperative CRPmax could provide a useful marker to predict prognosis in patients with stage II/III gastric cancer who underwent curative resection.

Interestingly, the high-CRPmax group in the present study was significantly associated with hematogenous metastasis as the pattern of recurrence. Similar to our result, Kurokawa et al. reported that liver metastasis, but not peritoneal or lymph node metastasis, was significantly more frequent in the high-CRPmax group than in the low-CRPmax group. Although the exact mechanisms underlying this association between higher postoperative inflammation and hematogenous metastasis remain unclear, some potential explanations can be considered. First, host immunosuppressive influences such as impairment of cellular immunity caused by the surgical stress could negatively impact on circulating tumor cells (CTCs) and micro-metastatic cancer cells. Although natural killer cells and macrophages play important roles in eliminating CTCs and preventing the formation of metastases, both the cytotoxicity of natural killer cells and macrophage function are reportedly impaired in proportion to the extent and magnitude of surgery. Extraperitoneal tumor growth was demonstrated to be accelerated accompanied by suppressed natural killer cell cytotoxicity after surgery. Second, systemic inflammation could accelerate the adhesion of CTCs to distant organs. E-selectin up-regulation, induced by inflammatory cells and pro-inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-α, has been shown to promote recruitment of CTCs to the vascular endothelium. Third, growth factors and cytokines such as TNF-α, vascular endothelial growth factor and IL-6 induced by the inflammatory response could promote the proliferation and metastasis of residual cancer cells. Thus, not only optimizing surgical procedures, but also immunomodulatory approaches and anti-inflammatory approaches in the perioperative period might improve oncological outcomes.

In the present study, postoperative infectious complications were not an independent prognostic factor for OS and RFS, despite significant associations with those outcomes in univariate analyses. Some studies have demonstrated that postoperative complications correlate with prognosis in gastric cancer patients, whereas others have not. This inconsistency may be attributable to differences in the definition and frequency of postoperative complications among studies. Moreover, most studies did not enter postoperative inflammatory responses (including surgical stress) into multivariate analyses for survival. Our findings suggest that systemic inflammatory response induced by not only postoperative complications, but also surgical stress is more important than the actual postoperative complications as a prognostic factor in patients with advanced gastric cancer.

In the present study, because the 71 patients with postoperative infectious complications included only three patients with high-CRPmax, we evaluated another cut-off value of CRPmax for patients with postoperative infectious complications. Consequently, patients with postoperative infectious complications and a high-CRPmax of >26.2 mg/dL revealed poorer OS than those with low-CRPmax ≤ 26.2 mg/dL. This finding suggests that the magnitude of systemic inflammatory response caused by infection could affect OS. When postoperative infectious complications occur, early diagnosis and appropriate treatment for infectious complications may be important to reduce systemic inflammatory response and improve long-term outcomes in patients with stage II/III gastric cancer.

From Japan, some important surgical randomized controlled trials for advanced gastric cancer have been reported by the Japan Clinical Oncology Group (JCOG). The JCOG9501 study compared D2 lymphadenectomy alone with D2 lymphadenectomy plus para-aortic nodal dissection for advanced gastric cancer without clinical para-aortic lymph node metastasis. The JCOG0110 study compared spleen preservation with spleenectomy for advanced proximal gastric cancer not involving the greater curvature. The JCOG1001 study compared non-bursectomy with bursectomy for advanced gastric cancer with cT3 (SS)-cT4b (SI). None of these studies demonstrated the prognostic efficacy of extended surgery. One reason why extended surgery uniformly failed to improve survival may be that the negative impact on residual cancer cells of the systemic inflammatory
response involved in surgical stress and postoperative complications may offset any positive impact of extended surgery. Furthermore, the JCOG9502 study compared an abdominal–transhiatal approach with a left thoracoabdominal approach for advanced gastric cancer with esophageal invasion of ≤3 cm revealed worse survival in the left thoracoabdominal approach group. In the JCOG9502 study, the rate of postoperative complications was higher in the left thoracoabdominal approach group and surgical stress was obviously larger in that same group. The impact of postoperative systemic inflammatory response induced by surgical stress and postoperative complications on survival may warrant more attention from general surgeons.

This study has some potential limitations that should be considered when interpreting the results. First, this retrospective study was conducted at a single institution and sample size was relatively small. Second, the present study showed heterogeneity in the adjuvant chemotherapy regimens, because the indications for and standard regimens of adjuvant chemotherapy had not been established until 2007, when the results of the ACTS-GC trial confirmed the efficacy of S-1 as adjuvant chemotherapy for stage II/III gastric cancer. However, in the subgroup analysis with or without adjuvant chemotherapy, OS rates were significantly lower in the high-CRPmax group than in the low-CRPmax group. Prospective large-scale validation studies are needed to confirm our findings.

Conclusion

CRPmax, which reflects the magnitude of systemic inflammation induced by surgical stress and postoperative complications in the early phase after surgery, is associated with oncologic outcome in patients with stage II/III gastric cancer who underwent curative resection. Our findings suggest that surgeons should not underestimate the prognostic impact of surgical stress and postoperative complications in the management of advanced gastric cancer. To improve long-term outcomes for advanced gastric cancer patients, reducing surgical stress and postoperative complications may be important.

Methods

Patients. This retrospective analysis investigated consecutive patients who underwent radical gastrectomy for gastric cancer at Osaka City University Hospital (Osaka, Japan) between January 2000 and December 2013. Patients diagnosed with stage II/III gastric cancer on postoperative pathological examination were enrolled in this study. We excluded 23 patients who underwent neoadjuvant chemotherapy, 33 patients with concomitant multiple cancers, 27 patients with R1/2 resection, 9 patients with specific histological type, 6 patients with peripancreatic death, and 13 patients for whom the full set of clinical data was not available. Ultimately, 444 patients were included in this study. The Osaka City University Ethics Committee approved this retrospective study of clinical data (approval no. 4386), which was conducted in accordance with the principles of the Declaration of Helsinki.

Data collection and evaluation of postoperative inflammatory response. We evaluated clinico-pathological characteristics including age, sex, body mass index (BMI), Eastern Cooperative Oncology Group performance status (PS), blood test examination data, operative approach and procedure, operation time, blood loss, tumor size, depth of invasion, lymph node metastasis, pathological stage, tumor location, histology, macroscopic type, lymphatic invasion, venous invasion, postoperative infectious complication, and adjuvant chemotherapy from medical records. Tumors were staged according to the third English edition of the Japanese classification of gastric carcinoma. Subjects were categorized according to age as elderly (≥75 years) and non-elderly (<75 years), and according to BMI as underweight (BMI < 18.5 kg/m²) and normal or overweight (BMI ≥ 18.5 kg/m²). In the present study, postoperative infectious complications included intra-abdominal abscess, anastomotic leakage, pancreatic fistula, pneumonia, surgical site infection, acute cholecystitis, and enteritis of Grade 2 or higher according to the Clavien–Dindo classification.

Serum CRP and WBC count were measured routinely on postoperative day (POD) 1, POD 3, and POD 6 or 7. In addition, serum CRP and WBC count were assessed when postoperative complications were suspected and when treatment efficacy was evaluated. We defined the maximum serum CRP level (CRPmax) and maximum WBC count (WBCmax) as the highest levels of those parameters identified during the entire interval from surgery until discharge. To set cut-off values for CRPmax and WBCmax, time-dependent receiver operating characteristic (ROC) curve analyses for 5-year overall survival (OS) as the endpoint were calculated, and maximal Youden indices were estimated. All patients were classified as having high or low values according to these cut-offs. In the present study, postoperative infectious complications were defined as postoperative complications accompanied by elevated CRP needing antibiotics, drainage and surgery. To diagnose infectious complications, blood examination, measurement of amylase in drain fluid, and imaging studies, such as computed tomography, ultrasonography and contrast swallow, were performed based on clinical suspicion. The attending surgeons performed each examination and recorded the results. Consequently, we included 24 cases of anastomotic leakage, 24 cases of pancreatic fistula, 7 cases of intra-abdominal abscess, 7 cases of surgical site infection, 3 cases of pneumonia, 2 cases of acute cholecystitis, 1 case of acute pancreatitis, 1 case of enteritis, 1 case of urinary tract infection, and 1 case of catheter-related bloodstream infection as Grade 2 or higher according to the Clavien-Dindo classification.

Treatment and follow-up. Surgical procedures were determined according to tumor size, location, and the status of resection margins. Laparoscopic surgery was preferred when clinical stage was less than stage I B. In principle, adjuvant chemotherapy with oral fluoropyrimidines (5-fluorouracil, uracil-tegafur, doxifluridine, or S-1) was administered after obtaining written informed consent, except for patients with pathological T1. Patients were routinely followed-up every 4 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter. Each follow-up examination included physical examinations, routine blood tests, measurements of tumor marker levels, and contrast-enhanced computed tomography of the abdomen. These same
Statistical analysis. Statistical analysis was performed using R for Mac OS X version 3.5.2 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). The χ² test or Fischer’s test was used to analyze associations between categorical variables, and the Mann–Whitney U test was used to compare continuous variables. Overall survival (OS) and relapse-free survival (RFS) were defined as the time from the date of surgery to the date of last follow-up or death, and the time from the date of surgery to the date of confirmed recurrence or death, respectively. OS and RFS were calculated using Kaplan–Meier methods, and survival curves were compared by log-rank testing. Uni- and multivariate analyses for OS and RFS were conducted with Cox proportional hazards models. We performed multivariate analyses including variables with values of p < 0.1 in univariate analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. We considered values of p < 0.05 as significant.

Received: 5 September 2021; Accepted: 3 February 2022
Published online: 22 February 2022

References
1. Global Burden of Disease Cancer, C. et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 3, 524–548, doi:https://doi.org/10.1001/jamaoncol.2016.5688 (2017).
2. Katayama, A. et al. Five-year survival analysis of surgically resected gastric cancer in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer 21, 144–154. https://doi.org/10.1007/s10120-017-0717-7 (2018).
3. Candido, J. & Hagemann, T. Cancer-related inflammation. J Clin Immunol 33(Suppl 1), S79–84. https://doi.org/10.1007/s10875-012-9847-0 (2013).
4. Tsujimoto, H. et al. Role of postoperative infection in long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol 16, 311–318. https://doi.org/10.1245/s10434-008-0249-8 (2009).
5. Tokunaga, M. et al. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol 20, 1575–1583. https://doi.org/10.1245/s10434-012-2720-9 (2013).
6. Hayashi, T. et al. Impact of infectious complications on gastric cancer recurrence. Gastric Cancer 18, 368–374. https://doi.org/10.1007/s10120-014-0361-3 (2015).
7. McPherson, K. & Stephens, R. Postoperative respiratory complications. Br J Hosp Med (Lond) 77, C60–64. https://doi.org/10.12968/hmed.2016.77.4.C60 (2016).
8. Kimura, F. et al. Immunosuppression following surgical and traumatic injury. Surg Today 40, 793–808. https://doi.org/10.1007/s00595-010-4323-z (2010).
9. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899. https://doi.org/10.1016/j.cell.2010.01.025 (2010).
10. Kono, Y. et al. Prognostic ratio of the maximum C-reactive protein level to the minimum peripheral lymphocyte count as a prognostic indicator for gastric cancer patients. Surg Today 49, 206–213. https://doi.org/10.1007/s00595-018-1724-x (2019).
11. Okumura, Y. et al. Prolongated inflammatory response as a poor prognostic factor after curative resection for gastric cancer. World J Surg 41, 2611–2618. https://doi.org/10.1007/s00268-017-4032-5 (2017).
12. Saito, T. et al. Which is a more reliable indicator of survival after gastric cancer surgery: postoperative complication occurrence or C-reactive protein elevation?. J Surg Oncol 112, 894–899. https://doi.org/10.1002/jso.24067 (2015).
13. Toyokawa, T. et al. Postoperative inflammation is an independent prognostic factor in patients with thoracic esophageal squamous cell carcinoma. Anticancer Res 39, 2777–2784. https://doi.org/10.21873/anticancerres.13404 (2019).
14. Kurokawa, Y. et al. Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study. Gastric Cancer 23, 937–943. https://doi.org/10.1007/s10120-020-01073-5 (2020).
15. Matsuda, S. et al. Correlation between intense postoperative inflammatory response and survival of esophageal cancer patients who underwent transthoracic esophagectomy. Ann Surg Oncol 22, 4453–4460. https://doi.org/10.1245/s10434-015-4557-5 (2015).
16. Ibusi, Y. et al. Role of postoperative C-reactive protein levels in predicting prognosis after surgical treatment of esophageal cancer. World J Surg 41, 1558–1565. https://doi.org/10.1007/s00268-017-3900-3 (2017).
17. McSorley, S. T. et al. Postoperative systemic inflammatory response, complication severity, and survival following surgery for colorectal cancer. Ann Surg Oncol 23, 2832–2840. https://doi.org/10.1111/asop.15204 (2016).
18. Rushfeldt, C. et al. Early events of hepatic metastasis formation in mice: role of Kupfer and NK-cells in natural and interferon-gamma-stimulated defense. J Surg Res 82, 209–215. https://doi.org/10.1016/j.jscr.1998.5552 (1999).
19. Oosterling, S. J. et al. Macrophages direct tumour histiology and clinical outcome in a colon cancer model. J Pathol 207, 147–155. https://doi.org/10.1002/path.1830 (2005).
20. Da Costa, M. L. et al. Laparotomy and laparoscopy differentially accelerate experimental flank tumour growth. Br J Surg 85, 1439–1442. https://doi.org/10.1002/bjs.908 (1998).
21. Nojiri, T. et al. Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells. Proc Natl Acad Sci USA 112, 4086–4091. https://doi.org/10.1073/pnas.1412737112 (2015).
22. Hiratsuka, S. et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci USA 108, 3725–3730. https://doi.org/10.1073/pnas.1100446108 (2011).
23. van der Bij, G. J. et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg 249, 727–734. https://doi.org/10.1097/SLA.0b013e3181a3ddd8 (2009).
24. Angelo, L. S. & Kurzrock, R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13, 2823–2830. https://doi.org/10.1158/1078-0432.CCR-06-2416 (2007).
25. Climent, M. et al. Postoperative complications do not impact on recurrence and survival after curative resection of gastric cancer. Eur J Surg Oncol 42, 132–139. https://doi.org/10.1016/j.ejso.2015.08.163 (2016).
26. Kim, S. H. et al. Risk factors for anastomotic leakage: a retrospective cohort study in a single gastric surgical unit. J Gastric Cancer 15, 167–173. https://doi.org/10.2530/jgc.2015.15.3.167 (2015).
27. Sasako, M. et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359, 453–462. https://doi.org/10.1056/NEJMoa0707035 (2008).
28. Sano, T. et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 265, 277–283. https://doi.org/10.1097/SLA.0000000000001814 (2017).
29. Kurokawa, Y. et al. BURsectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 3, 460–468. https://doi.org/10.1016/S2468-1253(18)30090-6 (2018).
30. Sasako, M. et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 7, 644–651. https://doi.org/10.1016/S1470-2045(06)70766-5 (2006).
31. Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357, 1810–1820. https://doi.org/10.1056/NEJMoa0722322 (2007).
32. Jung, H. et al. Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer 117, 2371–2378, doi:https://doi.org/10.1002/cncr.25778 (2011).
33. Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240, 205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae (2004).

Author contributions
Conceptualization: K.K. and T.T.; Data curation: K.K., T.T., Y.M., M.Y., T.T., H.T., S.L., K.M., and M.Y.; Formal analysis: K.K. and T.T.; Investigation: K.K., T.T. and Y.M.; Methodology: K.K. and T.T.; Project administration: T.T.; Resources: T.T., Y.M., Y.M., M.Y., T.T., H.T., S.L., K.M., M.Y., and M.O.; Supervision: M.O.; Writing-original draft: K.K.; Writing-review & editing: T.T. and M.O.; All authors have read and approved the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022